Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,773 signal articles · 68 in last 24h · 148,348 total before filter · latest 1h ago
68last 24h
974last 7d
109● bullish (7d)
123● bearish (7d)
212publishers
AllMacro369Earnings115M&A98Regulatory8Product11Analyst10
✕ clear all filtersticker: MSSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Morgan Stanley Sees Wealth, AI Financing and Deal Rebound Powering Growth
MarketBeat3d agoneutral
Morgan Stanley Sees Wealth, AI Financing and Deal Rebound Powering Growth

Morgan Stanley (NYSE:MS) Co-President Dan Simkowitz said the firm does not view 2026 as a peak-earnings year, citing growth opportunities in wealth management, a developing capital-markets recovery and continued financing demand tied to artificial intelligence. Speaking at an investor conference, S

Is Matson (MATX) Still Below Fair Value As It Heads To Morgan Stanley's Laguna Conference?
Simply Wall St.3d agoneutral
Is Matson (MATX) Still Below Fair Value As It Heads To Morgan Stanley's Laguna Conference?

Matson (MATX) heads into Morgan Stanley's 14th Annual Laguna Conference on 15 September, with investors watching how management frames the ocean transport and logistics outlook and what that might imply for the valuation. Recent trading has been strong, with Matson’s share price at $236.62 after a 1-day share price return of 2.80% and a 30-day share price return of 8.89%. The year-to-date share price return of 91.27% and 1-year total shareholder return of 127.22% point to building momentum...

Lilly’s Obesity Access Push via Medicare Bridge Might Change The Case For Investing In Eli Lilly (LLY)
Simply Wall St.4d agoneutral
Lilly’s Obesity Access Push via Medicare Bridge Might Change The Case For Investing In Eli Lilly (LLY)

Eli Lilly and Company recently presented at Morgan Stanley’s Global Healthcare Conference, where executive vice president Ilya Yuffa outlined efforts to expand access to its obesity medicines, including Zepbound and Foundayo, and highlighted broader international growth initiatives. This focus on widening obesity treatment access through consumer advertising, Medicare Bridge support, and global reach underlines how central these therapies have become to Lilly’s long-term business mix. We’ll...

Investing.com5d agoneutral
Morgan Stanley raises Target Hospitality PT on accretive contract win

Investing.com -- Morgan Stanley raised its price target on the lodging services provider to $25 from $22, citing an accretive contract win in its West Texas home territory and growing conviction in near-term execution on its pipeline. The broker reiterated its "overweight" rating.

Morgan Stanley Sees 25% Meta Gain on AI Upside
24/7 Wall St.9d agoneutral
Morgan Stanley Sees 25% Meta Gain on AI Upside

Meta shares remain deep in the red over the past year, yet one Morgan Stanley analyst just staked out a target that towers above Wall Street consensus and hinges on an AI bet most investors have not fully priced in.